Zealand Pharma A/S (ZLDPF) Expected to Announce Quarterly Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) is projected to issue its Q4 2024 quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect Zealand Pharma A/S to post earnings of ($0.78) per share and revenue of $28.11 million for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.19. The firm had revenue of $1.30 million for the quarter, compared to analysts' expectations of $28.11 million. Zealand Pharma A/S had a negative return on equity of 18.49% and a negative net margin of 1,375.16%. On average, analysts expect Zealand Pharma A/S to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock remained flat at $108.30 on Friday. The stock had a trading volume of 20 shares, compared to its average volume of 319. The firm has a market capitalization of $7.69 billion, a PE ratio of -44.57 and a beta of 0.88. The stock's 50 day simple moving average is $102.06 and its 200-day simple moving average is $113.67. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a one year low of $67.58 and a one year high of $141.74.

Analysts Set New Price Targets

Several research firms have weighed in on ZLDPF. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, January 21st. JPMorgan Chase & Co. started coverage on Zealand Pharma A/S in a research note on Friday, November 8th. They set an "overweight" rating on the stock.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.